BR112017000519A2 - "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica" - Google Patents
"composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"Info
- Publication number
- BR112017000519A2 BR112017000519A2 BR112017000519A BR112017000519A BR112017000519A2 BR 112017000519 A2 BR112017000519 A2 BR 112017000519A2 BR 112017000519 A BR112017000519 A BR 112017000519A BR 112017000519 A BR112017000519 A BR 112017000519A BR 112017000519 A2 BR112017000519 A2 BR 112017000519A2
- Authority
- BR
- Brazil
- Prior art keywords
- protecting
- immunogenic composition
- mammal against
- against meningococcal
- meningococcal infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14177563 | 2014-07-17 | ||
| PCT/EP2015/066229 WO2016008961A1 (en) | 2014-07-17 | 2015-07-16 | Meningococcus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017000519A2 true BR112017000519A2 (pt) | 2017-11-21 |
Family
ID=51178811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017000519A BR112017000519A2 (pt) | 2014-07-17 | 2015-07-16 | "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica" |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11707513B2 (enExample) |
| EP (1) | EP3169358A1 (enExample) |
| JP (2) | JP6687597B2 (enExample) |
| KR (2) | KR20230012100A (enExample) |
| CN (2) | CN106659776A (enExample) |
| AR (2) | AR101225A1 (enExample) |
| AU (2) | AU2015289193A1 (enExample) |
| BE (1) | BE1022878B1 (enExample) |
| BR (1) | BR112017000519A2 (enExample) |
| CA (1) | CA2954729C (enExample) |
| EA (1) | EA038940B1 (enExample) |
| IL (1) | IL249823B (enExample) |
| MX (1) | MX2017000775A (enExample) |
| SG (2) | SG10201900041VA (enExample) |
| WO (1) | WO2016008961A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015222121B2 (en) | 2014-02-28 | 2018-01-18 | Glaxosmithkline Biologicals Sa | Modified meningococcal fHbp polypeptides |
| US11707513B2 (en) | 2014-07-17 | 2023-07-25 | Glaxosmithkline Biologicals Sa | Meningococcus vaccines |
| EP3169357B1 (en) | 2014-07-17 | 2018-11-07 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| WO2017075189A1 (en) * | 2015-10-27 | 2017-05-04 | University Of Massachusetts | Factor h-fc immunotherapy |
| CN107151270B (zh) * | 2017-03-22 | 2018-07-31 | 武汉博沃生物科技有限公司 | 重组ΔfHbp-NadA融合蛋白载体及其制备方法和应用 |
| CN108939061A (zh) * | 2018-08-03 | 2018-12-07 | 北京智飞绿竹生物制药有限公司 | 一种多组分b群脑膜炎球菌疫苗及其制备方法 |
| EP3607967A1 (en) * | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| US11014736B2 (en) | 2019-04-18 | 2021-05-25 | Altria Client Services Llc | Sliding packs with flip top hinged lids |
| CN110804101A (zh) * | 2019-11-08 | 2020-02-18 | 苏州微超生物科技有限公司 | B群脑膜炎球菌相关融合蛋白、疫苗及其制备方法与应用 |
| KR20220152402A (ko) * | 2019-11-25 | 2022-11-15 | 그리피스 유니버시티 | 임균 감염에 대한 면역원성 단백질 |
| GB202115151D0 (en) | 2021-10-21 | 2021-12-08 | Glaxosmithkline Biologicals Sa | Methods |
| WO2025077785A1 (zh) * | 2023-10-10 | 2025-04-17 | 康希诺生物股份公司 | 一种抗脑膜炎球菌的免疫组合物及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| CA2871789C (en) * | 2000-01-17 | 2017-04-04 | Novartis Vaccines And Diagnostics S.R.L. | Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins |
| GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
| GB0419627D0 (en) * | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| US20130022633A1 (en) | 2009-10-27 | 2013-01-24 | University Of Florence | MENINGOCOCCAL fHBP POLYPEPTIDES |
| JP2013521326A (ja) | 2010-03-10 | 2013-06-10 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| BR122021020829B8 (pt) | 2010-03-30 | 2022-12-27 | Children´S Hospital & Res Center At Oakland | Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada |
| GB201015132D0 (en) | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
| GB201120634D0 (en) | 2011-11-30 | 2012-01-11 | Univ Sheffield | Adjuvant polypeptide |
| WO2013186753A1 (en) * | 2012-06-14 | 2013-12-19 | Novartis Ag | Vaccines for serogroup x meningococcus |
| GB201215005D0 (en) | 2012-08-23 | 2012-10-10 | Isis Innovation | Stabilised meningitis vaccine |
| AU2015222121B2 (en) * | 2014-02-28 | 2018-01-18 | Glaxosmithkline Biologicals Sa | Modified meningococcal fHbp polypeptides |
| EP2916512B1 (en) | 2014-03-07 | 2016-08-24 | Mitsubishi Electric R&D Centre Europe B.V. | Method for classifying a TCP connection carrying HTTP traffic as a trusted or an untrusted TCP connection |
| EP3169357B1 (en) | 2014-07-17 | 2018-11-07 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| US11707513B2 (en) | 2014-07-17 | 2023-07-25 | Glaxosmithkline Biologicals Sa | Meningococcus vaccines |
| ES2990193T3 (es) | 2018-06-21 | 2024-11-29 | Basf Se | Derivados de difosfato de 3-fenilbenzofuran-2-ona como estabilizadores |
-
2015
- 2015-07-16 US US15/319,665 patent/US11707513B2/en active Active
- 2015-07-16 SG SG10201900041VA patent/SG10201900041VA/en unknown
- 2015-07-16 WO PCT/EP2015/066229 patent/WO2016008961A1/en not_active Ceased
- 2015-07-16 CN CN201580038773.1A patent/CN106659776A/zh active Pending
- 2015-07-16 IL IL249823A patent/IL249823B/en unknown
- 2015-07-16 SG SG11201610946YA patent/SG11201610946YA/en unknown
- 2015-07-16 KR KR1020237001115A patent/KR20230012100A/ko not_active Ceased
- 2015-07-16 MX MX2017000775A patent/MX2017000775A/es unknown
- 2015-07-16 CN CN202111134597.5A patent/CN113827712A/zh active Pending
- 2015-07-16 EP EP15738900.8A patent/EP3169358A1/en active Pending
- 2015-07-16 KR KR1020177004245A patent/KR102626831B1/ko active Active
- 2015-07-16 BE BE2015/5455A patent/BE1022878B1/fr not_active IP Right Cessation
- 2015-07-16 AR ARP150102269A patent/AR101225A1/es not_active Application Discontinuation
- 2015-07-16 JP JP2017502625A patent/JP6687597B2/ja active Active
- 2015-07-16 EA EA201692554A patent/EA038940B1/ru unknown
- 2015-07-16 BR BR112017000519A patent/BR112017000519A2/pt not_active Application Discontinuation
- 2015-07-16 AU AU2015289193A patent/AU2015289193A1/en not_active Abandoned
- 2015-07-16 CA CA2954729A patent/CA2954729C/en active Active
-
2019
- 2019-02-18 AU AU2019201131A patent/AU2019201131C1/en active Active
-
2020
- 2020-04-02 JP JP2020066808A patent/JP7074793B2/ja active Active
-
2023
- 2023-06-06 US US18/329,701 patent/US12485164B2/en active Active
- 2023-10-17 AR ARP230102768A patent/AR130778A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE1022878A1 (fr) | 2016-09-30 |
| JP6687597B2 (ja) | 2020-04-22 |
| AU2015289193A1 (en) | 2017-02-02 |
| US20230414736A1 (en) | 2023-12-28 |
| WO2016008961A1 (en) | 2016-01-21 |
| CN106659776A (zh) | 2017-05-10 |
| AR130778A2 (es) | 2025-01-15 |
| EA038940B1 (ru) | 2021-11-12 |
| AR101225A1 (es) | 2016-11-30 |
| SG11201610946YA (en) | 2017-01-27 |
| CA2954729C (en) | 2023-08-22 |
| AU2019201131A1 (en) | 2019-03-07 |
| JP2017522319A (ja) | 2017-08-10 |
| AU2019201131C1 (en) | 2021-03-18 |
| JP7074793B2 (ja) | 2022-05-24 |
| CA2954729A1 (en) | 2016-01-21 |
| KR20170029615A (ko) | 2017-03-15 |
| CN113827712A (zh) | 2021-12-24 |
| US20180214531A1 (en) | 2018-08-02 |
| EP3169358A1 (en) | 2017-05-24 |
| US12485164B2 (en) | 2025-12-02 |
| MX2017000775A (es) | 2017-05-04 |
| SG10201900041VA (en) | 2019-02-27 |
| US11707513B2 (en) | 2023-07-25 |
| KR102626831B1 (ko) | 2024-01-22 |
| IL249823B (en) | 2022-07-01 |
| BE1022878B1 (fr) | 2016-09-30 |
| JP2020117523A (ja) | 2020-08-06 |
| EA201692554A1 (ru) | 2017-07-31 |
| AU2019201131B2 (en) | 2020-08-27 |
| KR20230012100A (ko) | 2023-01-25 |
| IL249823A0 (en) | 2017-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017000519A2 (pt) | "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica" | |
| MX2019005465A (es) | Metodo de tratamiento de un tumor inmunoterapeutico. | |
| CL2019003805A1 (es) | Composiciones inmunógenas de senecavirus a y métodos de éstas. | |
| BR112016014410A2 (pt) | terapia de combinação com vacina de neoantígeno | |
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| BR112017026739A2 (pt) | compostos para uso no tratamento de distúrbios neuromusculares | |
| BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
| AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
| JO3735B1 (ar) | مركبات ألكين بها استبدال رباعي واستخداماتها | |
| BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
| BR112012004806B8 (pt) | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso | |
| BR112013019257A2 (pt) | composição de androgênio para tratar uma condição oftálmica | |
| BR112013020743A2 (pt) | composições e métodos para a terapia e diagnóstico de influenza | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| BR112018074990A2 (pt) | composição, usos e método para reduzir neutropenia | |
| BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
| GT201500005A (es) | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue | |
| BR112015004515A2 (pt) | composição imunogênica | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
| BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
| BR112014000542A2 (pt) | composições de peroxidase eosinofílica e métodos de uso das mesmas | |
| BR112017004197A2 (pt) | composições de vacina contra doenças do vírus da dengue | |
| BR112017023448A2 (pt) | composições anti-fitopatogênicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |